CA
NZ
UK
AU
IND
US
Arrowhead Pharmaceuticals said on September 29, 2026 that it would host a webinar on Wednesday, October 14, 2026 at 11:30 a.m. PDT to present interim clinical data from a Phase 1/2a study of ARO-MAPT. Speakers included Dr. Adam Boxer of the University of California, …
● The latest earnings report showed a loss of $0.64 per share.
● Oculis does not currently plan an FDA filing for OCS-01 in diabetic macular edema.
● The net loss was $2,822,371, or $0.07 per share.
● A further US$1.3 billion from Moderna depends on an appellate ruling.
● Arbutus received US$178.4 million on 8 July 2026, its share of a US$950 million payment.
● Cash was US$31,944 at 30 June 2026, down from US$681,480 at year-end.
● Net loss was US$2,500,418 for the six months, with US$1,138,656 of operating cash used.
● Citibank, N.A. acts as depositary, under a deposit agreement governed by New York law.
● The first-half net loss widened to €165.9 million from €100.8 million.
Please wait processing your request...